Advanced Biomed (ADVB)
Financial-market AI systems with biomedical R&D pending sale.
Something off on this page? Send us feedback.
Develops FinLLM and FinTruth for regulated financial markets after shifting from biomedical R&D; the AI operation's pricing and commercial model have not been disclosed, and its Taiwan R&D subsidiary is pending sale.
Runs FinLLM, a financial-domain language model, and FinTruth, a verification system designed for precision, explainability, and compliance in regulated financial markets. The systems came with the acquisition of Hong Kong-based Acellent, which made AI the primary focus for a Nevada parent with its principal executive office in Tainan City, Taiwan.
Repeated corporate restructuring, including the AI acquisition and subsidiary sales, has been the clearest observed operating pattern. Retains, pending sale, the Taiwan subsidiary that conducts biomedical R&D, including the A+PerfusC perfusion cell-culture incubator and a legacy portfolio for circulating-tumor-cell workflows. Customer, pricing, and revenue data for the AI operation have not been disclosed, while biomedical products depend on applicable regulatory approvals before sale.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $2.6M · Total debt $712.5K · Total assets $10.6M · Shareholders' equity $9.2M
- Revenue
- $0
- Operating income
- −$519.8K
- Net income
- −$488.9K
No dividends on record.
| Insiders | 12.75% | 176.2K shares | |
|---|---|---|---|
| 1 holder · as of Aug 20, 2026 | |||
| Strategic holders | 7.90% | 109.2K shares | |
| 1 holder · as of Sep 22, 2026 | |||
| Other | 79.35% | 1.10M shares | |
| remainder | |||
1.38M company shares as of Sep 23, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Hung To Pau1Insider10 percent owner | 12.75% | 176,225 | filed Aug 20, 2026 |
ADVANCE ON VENTURES LtdStrategic | 7.90% | 109,200 | filed Sep 22, 2026 |
- Hung To Pau's transaction reports restate only vehicles that traded; the 2026 ownership statement (176.2K) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- IBM
Enterprise AI governance overlaps in verification and compliance.
- Moody's
Financial-market GenAI research competes in analyst workflows.
- Thomson Reuters
Audit and compliance AI overlaps in regulated finance workflows.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Advanced Biomed | $6.54 | +2.53% | $8.8M | — | — | — | — |
| IBM | $235.96 | +1.98% | $217.99B | 20.5 | 18.5 | 3.2 | +1.1% |
| Moody's | $474.99 | +1.22% | $81.27B | 29.8 | 26.7 | 10.0 | +15.1% |
| Thomson Reuters | $98.00 | +2.45% | $41.76B | 25.6 | 20.7 | 5.3 | +7.0% |
| Median | 25.6 | 20.7 | 5.3 | +7.0% |